This website contains promotional content and is intended for Healthcare Professionals based in the United Kingdom only. Some content may only be relevant to HCPs practising in Great Britain (England, Scotland and Wales) according to product availability. This website is optimised for desktop use, and some features may perform differently on mobile devices.

Adverse event reporting can be found at the bottom of the page.

  1. Article
  2. Source: Campus Sanofi
  3. 23 Jul 2025

Dosing options – customise your patient’s treatment with Praluent® (alirocumab)

Author: Sanofi

Editorial Team

   

.

Praluent logo

Prescribing Information (UK)

A 4-weekly (monthly) single injection

300 mg Q4W

A device you’ll recognise with one step less2,3

✅ No button to push

✅ Injection starts when device is pressed fully into the skin

✅ Designed to deliver once-monthly dose in ≤20 seconds4

Only PCSK9i with once-monthly single injection in a pre-filled pen1

✅ The potential to halve the administration days for your patients

Two twice-monthly options1

75 mg Q2W

150 mg Q2W

The recommended alirocumab doses are 75 mg once every 2 weeks, 150 mg once every 2 weeks, 300 mg once every 4 weeks (monthly), administered subcutaneously. All doses may be used for initiation of treatment.

Customised treatment with Praluent®

Dosage information

The dose of alirocumab can be individualised based on patient characteristics such as baseline LDL-C level, goal of therapy, and response to treatment. Lipid levels can be assessed 4 to 8 weeks after treatment initiation or titration, and dose adjusted accordingly (up-titration or down-titration). Intense LDL-C reduction is expected with alirocumab 150 mg once every 2 weeks, and 300 mg once every 4 weeks (monthly), where 150 mg once every 2 weeks is the maximum dose (see section 5.1 of the SmPC)

For full instructions on use refer to the Patient information Leaflet.

SEE MORE FROM SCIENCE

Praluent®

Find more information on Indication, Administration and Mechanism of Action and watch videos about Praluent®.

Patient Website

Find resources and support for your patients on Praluent®. Find useful links about how patients can manage their cholesterol.

Get in touch with the Dyslipidaemia Team
MAT-XU-2201545 (v5.0) Date of Preparation: October 2023
References

CV=cardiovascular; LDL-C=low-density lipoprotein cholesterol; Q2W=once every two weeks; Q4W=once every four weeks.

  1. Praluent Summary of Product Characteristics. Available at https://www.medicines.org.uk/emc/product/8093/smpc. Accessed July 2025.
  2. Praluent Patient information leaflet 150mg. July 2025.
  3. Praluent Patient information leaflet 300mg. July 2025.
  4. Frias JP, Koren MJ, Loizeau V, et al. The SYDNEY Device Study: A Multicenter, Randomized, Open-label Usability Study of a 2-mL Alirocumab Autoinjector Device. Clinical Therapeutics. 2020; 42(1):94-107.

MAT-XU-2503036 (v1.0) Date of Preparation: July 2025  

Related Content